InvestorsHub Logo
Followers 14
Posts 817
Boards Moderated 0
Alias Born 02/24/2010

Re: None

Sunday, 01/04/2015 12:03:47 AM

Sunday, January 04, 2015 12:03:47 AM

Post# of 403754
Here were my comments on that sad article:
Ben you shorted this just before the company Cellceutix is just about to give a comprehensive update on all their drug platforms at a Jan. 12 Biotech conference, not good Ben but then one can tell you really don't follow the company rather just shorted a stock that was moving up quickly.

Kevetrin: P53 reactivating drug could potentially treat over half the known cancers. Currently in late stage trial phase 1 at Harvard. This trial is already a success phase 2+ upcoming with proof of reactivation of p53 with elevated p21 at higher doses. Look for big break through here in pancreatic and colon cancers IMO.

Kevetrin: 1b/2 at University of Bologna for Leukemia at no cost to the company.

Kevetrin in renal cancer with Pfizer Sunitinib at Beth Israel Deaconess Medical Center where in preclinical work showed Kevetrin produced the first ever regression in resistant renal cancer. A SPORE grant will be paying for the human trials.

Brilacidin is part of a whole platform called defensin-mimetics which anti-infective drugs. Brilacidin just blew away top seller Daptomycin in a phase 2b trial where a one day dose of Brilacidin was comparable to a 7 day dose of Dapto in treatment of ABSSSI. This would be 100% patient compliance-HUGE! Brilacidin is a novel antibiotic of which none have been approved in the last 20 years! Brilacidin works by ripping off the plasma membrane of the bacteria....RESISTANCE will never have a chance to develop!

Brilacidin has just started a phase 2b trial for oral mucositis look for Break through status from the FDA here there is no other treatments for OM.

Cellceutix has made the compound stable at room temperature so they are now going after Diabetic foot infection $$$. Also planned trials for Brilacidin in otic and ocular applications. With the success in ABSSSI it bolds well for Brilacidin in all these other indications as well.

Oh, and there ~7 more compounds currently in the defensin-mimetics expect 2-3 trials to start here in 2015.

Oh yeah then there is Prurisol..but you probably already realized your mistake in shorting CTIX so I will let it end here.